These results match other studies in which the small molecule inhibitor NSC23677, targeting the small GTPase Rac1, was able to reduce the migratory capability of PC3 prostate cancer cells overexpressing constitutively active form of Rac1 [31,32]. This evidence concerns the gene RAC1 and prostate carcinoma.